Document Detail


Construction and functional evaluation of hirudin derivatives with low bleeding risk.
MedLine Citation:
PMID:  18278181     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to design and evaluate hirudin (HIR) derivatives with low bleeding risk. In these derivatives, the factor (F) XIa, FXa, and thrombin recognition peptides (EPR, GVYAR, and LGPR, respectively) were linked to the N-terminus of HIR. The intact derivatives have no anticoagulant activity because of the extension of the N-terminus of HIR. After cleavage by the corresponding coagulation factor that occurs on the activation of the coagulation system and in the presence of the thrombus, its activity is released. This limited the anticoagulant activity of these derivatives to the vicinity of the thrombus, and as a result, systemic bleeding complications were avoided. The definite antithrombotic effect and low bleeding parameters of these derivatives were investigated in rat carotid artery and inferior vena cava thrombosis models. In both models, the three derivatives showed significant antithrombotic effects, indicating that anticoagulant activity could be successfully released in vivo. Moreover, the bleeding parameters of these derivatives were lower than that of HIR as indicated by the values of activated partial thromboplastin time (APTT) and thrombin time (TT). To further assess the safety of these derivatives, bleeding time was measured in a mouse tail-cut model. Although the derivatives had obvious effects on bleeding at a dose of 6 mg/kg, the effect of these derivatives on bleeding was significantly weaker than that of HIR at a dose of 1.5 mg/kg. Thus, the benefit-to-risk profiles of the derivatives were superior to that of HIR.
Authors:
Chuanling Zhang; Aiping Yu; Bin Yuan; Chunna Dong; Hongyang Yu; Lisheng Wang; Chutse Wu
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  99     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-18     Completed Date:  2008-04-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  324-30     Citation Subset:  IM    
Affiliation:
Key Lab of Experimental Hematology, Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing, P. R. China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticoagulants / adverse effects,  metabolism,  pharmacology*
Bleeding Time
Blood Coagulation / drug effects*
Cloning, Molecular*
Disease Models, Animal
Dose-Response Relationship, Drug
Female
Fibrinolytic Agents / adverse effects,  metabolism,  pharmacology*
Hemorrhage / chemically induced*
Hirudins / adverse effects,  metabolism,  pharmacology*
Male
Mice
Partial Thromboplastin Time
Prodrugs / adverse effects,  metabolism,  pharmacology*
Rats
Rats, Wistar
Recombinant Fusion Proteins / pharmacology
Risk Assessment
Thrombin Time
Thrombosis / blood,  prevention & control*
Venous Thrombosis / blood,  prevention & control
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Hirudins; 0/Prodrugs; 0/Recombinant Fusion Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The antigenic binding sites of autoantibodies to factor XII in patients with recurrent pregnancy los...
Next Document:  Calibrated automated thrombin generation in normal uncomplicated pregnancy.